Conflicts of interest.
JPG: reports having received speaker fees, fees for board memberships
and travel support from Gilead, MSD and Pfizer; Grant to the University
Hospital of Rennes from the “Programme Hospitalier de Recherche
Clinique Interrégional” 2013-2020 of the French Ministry of Health for
ECENVIR study.
CG reports having received speaker fees, travel support from Pfizer,
MSD; fees for board memberships from SOS Oxygène and Pulmatrix; grant
support from Ohre Pharma, Pfizer, MSD, SOS Oxygène, ISIS Medical,
Vivisol, Elivie, and AstraZeneca. Material and logistics support to all
participating centres for NEBULAMB study from the firm PARI GmbH France.
Grant to the University Hospital of Poitiers from the “Programme
Hospitalier de Recherche Clinique Interrégional” 2012 of the French
Ministry of Health for NEBULAMB study and 2017 for CPAAARI study.
DWD and family hold Founder shares in F2G Ltd, a University of
Manchester spin-out antifungal discovery company, and share options in
TFF Pharma. He acts or has recently acted as a consultant to Pulmatrix,
Pulmocide, Biosergen, TFF Pharmaceuticals, Bright Angel Therapeutics,
Pfizer, Omega, Novacyt and Cipla. He sits on the DSMB for a SARS CoV2
vaccine trial. In the last 3 years, he has been paid for talks on behalf
of Hikma, Gilead, BioRad, Basilea, Mylan, Biorad and Pfizer. He is a
longstanding member of the Infectious Disease Society of America
Aspergillosis Guidelines group, the European Society for Clinical
Microbiology and Infectious Diseases Aspergillosis Guidelines group and
recently joined the One World Guideline for Aspergillosis.”
Author’s contribution. JPG, CG and DWD: conceptualization and
writing original draft.
Legend Figure 1. Fungal exposome impacts on lungs and
strategies of prevention of allergic fungal diseases. ABPA: allergic
broncho-pulmonary aspergillosis ; SAFS: severe asthma with fungal
sensitization.